Showing 1-4 of about 4 articles.
Sensus Healthcare, Inc.
Keloid recurrence rate of 10.4% at 12 months for patients treated with SRT following keloidectomy compares with more than 80% with surgical excision aloneRetrospective study published in Journal of...
Sensus Healthcare, Inc.
Beginning September 1, Category A credits will be available for in-person trainings on the SRT-100™, SRT-100+™ and SRT-100 Vision™ systems BOCA RATON, Fla, Aug. 05, 2020 (GLOBE NEWSWIRE) -- ...
Sensus Healthcare, Inc.
BOCA RATON, Fla. , July 28, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and...
Sensus Healthcare, Inc.
Influential professional organization recommends radiotherapy as the primary non-surgical alternative for patients with basal cell or cutaneous squamous cell carcinomas BOCA RATON, Fla, July 14,...
Showing 1-4 of about 4 articles.
